Cargando…
Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study
BACKGROUND: The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6–11 years with moderate-to-severe AD not adequately c...
Ejemplares similares
-
Prevalence of Chronic Inducible Urticaria in Elderly Patients
por: Napolitano, Maddalena, et al.
Publicado: (2021) -
Skin rashes after SARS‐CoV‐2 vaccine: which relationship, if any?
por: Patruno, Cataldo, et al.
Publicado: (2021) -
Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
por: Napolitano, Maddalena, et al.
Publicado: (2020) -
Delayed urticaria after the third dose of mRNA COVID19 vaccine: A case series
por: Bianchi, Leonardo, et al.
Publicado: (2022) -
Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
por: Miniotti, Marco, et al.
Publicado: (2022)